The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, CLOV and EBIX
NEW YORK, NY / ACCESSWIRE / February 24, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
bluebird bio, Inc. (NASDAQ:BLUE)
Class Period: May 11, 2020 - November 4, 2020
Lead Plaintiff Deadline: April 13, 2021
The BLUE lawsuit alleges bluebird bio, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in BLUE: http://www.kleinstocklaw.com/pslra-1/bluebird-bio-inc-loss-submission-form?id=13096&from=1
Clover Health Investments, Corp. (NASDAQ:CLOV)
Class Period: October 6, 2020 - February 3, 2021
Lead Plaintiff Deadline: April 6, 2021
Throughout the class period, Clover Health Investments, Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Clover was the recipient of a Civil Investigative Demand from the DOJ; (ii) much of Clover's sales are driven by a major related party deal that Clover not only failed to disclose but took active steps to conceal; (iii) Clover's
subsidiary Seek Insurance failed to disclose its relationship with Clover and misled consumers as to its purported independence; (iv) Clover's software was in fact rudimentary; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in CLOV: http://www.kleinstocklaw.com/pslra-1/clover-health-investments-corp-loss-submission-form?id=13096&from=1
Ebix, Inc. (NASDAQ:EBIX)
Class Period: November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline: April 23, 2021
The complaint alleges that throughout the class period Ebix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) that there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in EBIX: http://www.kleinstocklaw.com/pslra-1/ebix-inc-loss-submission-form?id=13096&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:The Klein Law Firm
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.